Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUET ENCORE-UC
ISRCTN15730771Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of guselkumab + golimumab, guselkumab and golimumab in autoimmune colitis (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of participants in clinical remission at Week 48. Started May 2026; status: recruiting.
02
Drugs
guselkumab + golimumabguselkumabgolimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on ISRCTN15730771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15730771.